Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment-Reference-Cited by-同舟云学术

Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment

Published:2014-04-01 Issue:8 Volume:74 Page:869-879
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Zhang Qiuyang¹,Liu Sen¹,Zhang Qingsong¹²,Xiong Zhenggang³,Wang Alun R.³,Myers Leann⁴,Melamed Jonathan⁵,Tang Wendell W.⁶,You Zongbing¹²⁷⁸⁹^ORCID

Affiliation:

1. Department of Structural & Cellular Biology; Tulane University; New Orleans Louisiana

2. Department of Orthopaedic Surgery; Tulane University; New Orleans Louisiana

3. Department of Pathology and Laboratory Medicine; School of Medicine; Tulane University; New Orleans Louisiana

4. Department of Biostatistics and Bioinformatics; School of Public Health and Tropical Medicine; Tulane University; New Orleans Louisiana

5. Department of Pathology; New York University School of Medicine; New York New York

6. Department of Pathology; Ochsner Clinic Foundation; New Orleans Louisiana

7. Tulane Cancer Center and Louisiana Cancer Research Consortium; Tulane University; New Orleans Louisiana

8. Tulane Center for Stem Cell Research and Regenerative Medicine; Tulane University; New Orleans Louisiana

9. Tulane Center for Aging; Tulane University; New Orleans Louisiana

Publisher

Wiley

Subject

Urology,Oncology

Reference49 articles.

1. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion;Harris;Nat Clin Pract Urol,2009

2. Androgen receptor gene mutations in human prostate cancer;Newmark;Proc Natl Acad Sci USA,1992

3. The androgen axis in recurrent prostate cancer;Mohler;Clin Cancer Res,2004

4. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer;Hu;Cancer Res,2009

5. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor;Culig;Cancer Res,1994

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Matrix metalloproteinases targeting in prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-09

2. BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression;JNCI: Journal of the National Cancer Institute;2024-06-04

3. Genetically modified organisms in urological cancer;Genetically Modified Organisms [Working Title];2024-05-22

4. Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy – obstacles and perspectives;Transcription;2024-03-28

5. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients;Cancer Immunology, Immunotherapy;2024-02-13